The University of Chicago Header Logo

Connection

David T. Rubin to Disease Progression

This is a "connection" page, showing publications David T. Rubin has written about Disease Progression.
Connection Strength

0.916
  1. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018 Mar; 47(6):753-762.
    View in: PubMed
    Score: 0.111
  2. Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 01; 23(1):152-157.
    View in: PubMed
    Score: 0.103
  3. The peri-appendiceal red patch in ulcerative colitis: review of the University of Chicago experience. Dig Dis Sci. 2010 Dec; 55(12):3495-501.
    View in: PubMed
    Score: 0.067
  4. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010 Aug; 16(8):1352-6.
    View in: PubMed
    Score: 0.066
  5. An updated approach to dysplasia in IBD. J Gastrointest Surg. 2008 Dec; 12(12):2153-6.
    View in: PubMed
    Score: 0.058
  6. p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease. Dig Dis Sci. 2008 Feb; 53(2):474-80.
    View in: PubMed
    Score: 0.053
  7. Colonic infiltration with chronic myelomonocytic leukemia. Nat Clin Pract Gastroenterol Hepatol. 2007 Apr; 4(4):229-33.
    View in: PubMed
    Score: 0.052
  8. The complexity and challenges of genetic counseling and testing for inflammatory bowel disease. J Genet Couns. 2006 Dec; 15(6):465-76.
    View in: PubMed
    Score: 0.051
  9. Surveillance for cancer and dysplasia in inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Sep; 35(3):581-604.
    View in: PubMed
    Score: 0.050
  10. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol. 2005 Jun; 100(6):1354-6.
    View in: PubMed
    Score: 0.046
  11. Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21). BMC Med Res Methodol. 2023 05 25; 23(1):129.
    View in: PubMed
    Score: 0.040
  12. What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented? Gastroenterology. 2022 04; 162(5):1396-1408.
    View in: PubMed
    Score: 0.036
  13. Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2021 10; 6(10):826-849.
    View in: PubMed
    Score: 0.035
  14. Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275.
    View in: PubMed
    Score: 0.030
  15. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 01; 13(1):50-57.
    View in: PubMed
    Score: 0.029
  16. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80.
    View in: PubMed
    Score: 0.025
  17. Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis. 2016 Dec; 10(12):1385-1394.
    View in: PubMed
    Score: 0.025
  18. Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. Inflamm Bowel Dis. 2016 May; 22(5):1027-31.
    View in: PubMed
    Score: 0.024
  19. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009 Feb 01; 29(3):247-57.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.